MedPath

Exploring the Role of Serum Methylmalonic Acid (MMA) in Breast Cancer

Completed
Conditions
Breast Cancer
Registration Number
NCT05352737
Lead Sponsor
KU Leuven
Brief Summary

This project aims to investigate the role of MMA in breast cancer. To this end, we will measure MMA on serum samples collected at the time of breast cancer diagnosis, to investigate the role of MMA in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty.

Detailed Description

This project aims to investigate the role of MMA in breast cancer. To this end, we will measure MMA on serum samples collected at the time of breast cancer diagnosis, to investigate the role of MMA in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty. If the role of baseline serum MMA in therapy resistance and/or metastasis is confirmed, our study could be further extended by evaluating SOX4 expression in the tumor tissues (SOX4 is activated by MMA, and SOX4 induces EMT (epithelial to mesenchymal transition) and the metastasis process.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
300
Inclusion Criteria
  1. Female patients older than 18 years at diagnosis.
  2. First diagnosis of invasive breast cancer.
  3. All pathological parameters are available to identify histological subtype according to standard procedures.
  4. Availability of frozen serum samples at diagnosis.
  5. Voluntarily signed Informed Consent obtained before blood drawing for biobanking was performed.
Exclusion Criteria
  1. Pregnant at diagnosis.
  2. stage 0 disease (in situ).
  3. Bilateral BC at diagnosis or multifocal unilateral BC with different histology.
  4. Other subtypes than Invasive ductal carcinoma.
  5. Prior breast cancer.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MMA levelsbaseline

baseline serum MMA levels in pre-defined patients

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Lab of Experimental Oncology

🇧🇪

Leuven, State Or Province:, Belgium

Lab of Experimental Oncology
🇧🇪Leuven, State Or Province:, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.